Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia

被引：13
作者：
George, Binsah [1 ]
Kantarjian, Hagop [1 ]
Jabbour, Elias [1 ]
Jain, Nitin [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
IMMUNOTHERAPY | 2016年 / 8卷 / 02期
关键词：
acute lymphoblastic leukemia; antibody drug conjugate; inotuzumab; monoclonal antibody; ACUTE LYMPHOCYTIC-LEUKEMIA; ANTIBODY-TARGETED CHEMOTHERAPY; ACUTE MYELOID-LEUKEMIA; B-CELL LYMPHOMAS; HYPER-CVAD; GEMTUZUMAB OZOGAMICIN; CD22-TARGETED IMMUNOCONJUGATE; MONOCLONAL-ANTIBODY; ANTITUMOR EFFICACY; ADHESION MOLECULE;
D O I：
10.2217/imt.15.108
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Inotuzumab ozogamicin is a humanized anti-CD22 monoclonal antibody bound to a toxic natural calicheamicin, which is under investigation for the treatment of relapsed/refractory acute lymphoblastic leukemia. CD22 is commonly expressed in 90-100% of malignant mature B-lymphocyte lineage. The first Phase II study with inotuzumab ozogamicin conducted by Kantarjian et al. gave the opportunity for heavily pretreated patients with acute lymphoblastic leukemia to go for allogeneic stem cell transplant. Inotuzumab is well-tolerated with the exception of veno-occlusive disease. Overall inotuzumab ozogamicin is potentially an encouraging and promising therapy for patients.
引用
收藏
页码：135 / 143
页数：9
相关论文
共 50 条
[41]   Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE [J].
Jabbour, Elias J. ;
DeAngelo, Daniel J. ;
Stelljes, Matthias ;
Stock, Wendy ;
Liedtke, Michaela ;
Gokbuget, Nicola ;
O'Brien, Susan ;
Wang, Tao ;
Paccagnella, M. Luisa ;
Sleight, Barbara ;
Vandendries, Erik ;
Advani, Anjali S. ;
Kantarjian, Hagop M. .
CANCER, 2018, 124 (08) :1722-1732
[42]   Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas [J].
Piccaluga, PP ;
Martinelli, G ;
Rondoni, M ;
Malagola, M ;
Gaitani, S ;
Isidori, A ;
Bonini, A ;
Gugliotta, L ;
Luppi, M ;
Morselli, M ;
Sparaventi, G ;
Visani, G ;
Baccarani, M .
LEUKEMIA & LYMPHOMA, 2004, 45 (09) :1791-1795
[43]   Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin [J].
Kebriaei, Partow ;
Wilhelm, Kaci ;
Ravandi, Farhad ;
Brandt, Mark ;
de Lima, Marcos ;
Ciurea, Stefan ;
Worth, Laura ;
O'Brien, Susan ;
Thomas, Deborah ;
Champlin, Richard E. ;
Kantarjian, Hagop .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (03) :296-301
[44]   Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia [J].
Contreras, Cristina F. ;
Higham, Christine S. ;
Behnert, Astrid ;
Kim, Kailyn ;
Stieglitz, Elliot ;
Tasian, Sarah K. .
PEDIATRIC BLOOD & CANCER, 2021, 68 (01)
[45]   Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial [J].
Jabbour, Elias ;
Goekbuget, Nicola ;
Advani, Anjali ;
Stelljes, Matthias ;
Stock, Wendy ;
Liedtke, Michaela ;
Martinelli, Giovanni ;
O'Brien, Susan ;
Wang, Tao ;
Laird, A. Douglas ;
Vandendries, Erik ;
Neuhof, Alexander ;
Nguyen, Kevin ;
Dakappagari, Naveen ;
DeAngelo, Daniel J. ;
Kantarjian, Hagop .
LEUKEMIA RESEARCH, 2020, 88
[46]   Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults [J].
Aharon Ronson ;
Ariella Tvito ;
Jacob M. Rowe .
Current Oncology Reports, 2016, 18
[47]   Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma [J].
Amandeep Aujla ;
Ravijot Aujla ;
Delong Liu .
Biomarker Research, 7
[48]   Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas [J].
Ohanian, Maro ;
Kantarjian, Hagop ;
Guy, Daniel ;
Thomas, Deborah ;
Jabbour, Elias ;
O'Brien, Susan .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (04) :601-611
[49]   Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia [J].
Morley, N. J. ;
Marks, D. I. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (02) :159-164
[50]   Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059 [J].
Wu, Jen-Hao ;
Pennesi, Edoardo ;
Bautista, Francisco ;
Garrett, May ;
Fukuhara, Kei ;
Brivio, Erica ;
Ammerlaan, Anneke C. J. ;
Locatelli, Franco ;
van der Sluis, Inge M. ;
Rossig, Claudia ;
Chen-Santel, Christiane ;
Bielorai, Bella ;
Petit, Arnaud ;
Stary, Jan ;
Diaz-de-Heredia, Cristina ;
Rives, Susana ;
O'Marcaigh, Aengus ;
Rizzari, Carmelo ;
Engstler, Gernot ;
Nysom, Karsten ;
Rubio-San-Simon, Alba ;
Bruno, Benedicte ;
Bertrand, Yves ;
Brethon, Benoit ;
Rialland, Fanny ;
Plat, Genevieve ;
Dirksen, Uta ;
Sramkova, Lucie ;
Zwaan, C. Michel ;
Huitema, Alwin D. R. .
CLINICAL PHARMACOKINETICS, 2024, 63 (07) :981-997
12345